2021
Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis
He S, Li G, Schätzlein AG, Humphrey PA, Weiss RM, Uchegbu IF, Martin DT. Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis. Cellular Signalling 2021, 81: 109931. PMID: 33529758, DOI: 10.1016/j.cellsig.2021.109931.Peer-Reviewed Original ResearchConceptsBladder cancer cellsCancer cellsHuman bladder cancer specimensCisplatin-based chemotherapyBladder cancer treatmentBladder cancer specimensChemoresistant bladder cancer cellsBreast cancer cellsCell viabilityBladder cancerCancer specimensSmall molecule inhibitorsLevels of Ku70Cancer treatmentKu70 expression
2019
Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth
Li X, He S, Tian Y, Weiss RM, Martin DT. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. Cellular Signalling 2019, 63: 109381. PMID: 31374291, DOI: 10.1016/j.cellsig.2019.109381.Peer-Reviewed Original ResearchMeSH KeywordsButadienesCarcinoma, Transitional CellCell Line, TumorCell MovementCell SurvivalDrug Resistance, NeoplasmDrug SynergismEnzyme InhibitorsGene Expression Regulation, NeoplasticGlycoproteinsHumansHydrazinesMAP Kinase Signaling SystemMitogen-Activated Protein Kinase 1NitrilesQuinoxalinesUrinary Bladder NeoplasmsConceptsChemoresistant bladder cancerBladder cancer cellsBladder cancerInterleukin-6Clinical outcomesMultidrug resistanceGemcitabine-resistant bladder cancer cellsBladder cancer cell growthMajor treatment obstacleMetastatic bladder cancerPI3K/Akt/mTOR signalingCancer cellsResistant bladder cancer cellsPoor clinical outcomeAkt/mTOR SignalingSynergistic inhibitionNovel therapeutic strategiesPotential therapeutic targetMEK/ERK signalingCancer cell growthRaf/MEK/ERK signalingRole of gp130Therapeutic strategiesTreatment obstaclesTherapeutic targetGlycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target
Martin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.Peer-Reviewed Original ResearchConceptsBladder cancer cell linesBladder tumorsBladder cancerCancer cell linesHigh-grade bladder cancer cell linesCancer xenograft mouse modelBladder cancer growthAggressive bladder cancerPotential therapeutic targetHuman bladder tumorsXenograft mouse modelBladder cancer progressionCell linesBladder tumor cellsCurative potentialOptimal treatmentTumor gradePatient outcomesReduced cell migrationTumor volumeTumor categoryMouse modelTherapeutic targetTumor aggressivenessCancer growth
2014
Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer
Martin DT, Steinbach JM, Liu J, Shimizu S, Kaimakliotis HZ, Wheeler MA, Hittelman AB, Saltzman W, Weiss RM. Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer. Molecular Cancer Therapeutics 2014, 13: 71-81. PMID: 24222663, PMCID: PMC3924597, DOI: 10.1158/1535-7163.mct-13-0502.Peer-Reviewed Original ResearchConceptsBladder permeability barrierSurvivin siRNAChitosan delivery systemBladder cancerBladder diseaseTherapeutic responseTumor volumeXenograft tumorsMouse bladderTumor siteSurvivin expressionIntravesical deliveryHuman ureterTumor cell uptakeSiRNATumorsUnmodified nanoparticlesCell uptakeDelivery system
2013
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine Nanotechnology Biology And Medicine 2013, 9: 1124-1134. PMID: 23764660, PMCID: PMC3815967, DOI: 10.1016/j.nano.2013.05.017.Peer-Reviewed Original ResearchConceptsHistone deacetylase inhibitor belinostatBladder cancerBladder permeability barrierNon-invasive bladder cancerCultured bladder cancer cellsBladder cancer cellsChemotherapy efficacyIntravesical drug deliveryXenograft tumorsMouse bladderMouse modelConvincing dataHuman ureterBelinostatCancerCancer cellsLower IC50TumorsAcetyl-H4Tissue penetrationCLINICAL EDITORIntracellular uptakeDeliveryCellsPatients
2010
Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C
Verma A, DeGrado J, Hittelman AB, Wheeler MA, Kaimakliotis HZ, Weiss RM. Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C. BJU International 2010, 107: 1154-1161. PMID: 20735383, DOI: 10.1111/j.1464-410x.2010.09543.x.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorVascular endothelial growth factor receptor 2Bladder cancer cellsVEGF receptor 1Bladder of ratsEndothelial growth factorVEGFR-2 mRNAMitomycin CVEGFR-2 proteinCancer cellsSurvivin siRNAVEGF concentrationsMMC concentrationsUrinary vascular endothelial growth factorGrowth factorVEGFR-2 concentrationsGrowth factor receptor 2Superficial bladder cancerTransitional cell carcinomaMMC treatmentEndothelial growth factor receptor 2Factor receptor 2Interleukin-6 mRNAEffective intravesical treatmentLower MMC concentrations
2006
A role for Akt in the rapid regulation of inflammatory and apoptotic pathways in mouse bladder
Tamarkin FJ, Kang WS, Cohen JJ, Wheeler MA, Weiss RM. A role for Akt in the rapid regulation of inflammatory and apoptotic pathways in mouse bladder. Naunyn-Schmiedeberg's Archives Of Pharmacology 2006, 373: 349-359. PMID: 16832691, DOI: 10.1007/s00210-006-0081-2.Peer-Reviewed Original ResearchConceptsApoptotic pathwayPI3KAkt phosphorylationNon-phosphorylated speciesPhosphatidylinositol-3 kinaseNF-κBPhosphorylation of AktPI3K/AktCellular signalingTranscription factorsForkhead familyPI3K inhibitorsNF-κB phosphorylationKappa BDownstream pathwaysAkt activationInhibitor kappa BPhosphorylationRapid regulationAktProtein amountNuclear factor kappa BK inhibitorsCancer cellsUrothelial cancer cells
2005
A Survivin Gene Signature Predicts Aggressive Tumor Behavior
Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC. A Survivin Gene Signature Predicts Aggressive Tumor Behavior. Cancer Research 2005, 65: 3531-3534. PMID: 15867343, DOI: 10.1158/0008-5472.can-04-4284.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsButylhydroxybutylnitrosamineCarcinogensDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInhibitor of Apoptosis ProteinsMembrane ProteinsMiceMice, TransgenicMicrotubule-Associated ProteinsNeoplasm ProteinsPolymerase Chain ReactionSurvivinTransgenesTumor Suppressor Protein p53Urinary BladderUrinary Bladder NeoplasmsUroplakin IIConceptsTransgenic expressionGene signatureGlobal transcriptional changesDominant negative mutantGene expression profilesSuch genesTumor progressionTranscriptional changesCell divisionEssential regulatorGene expressionExpression profilesTransgenic animalsExtracellular matrixTissue microenvironmentAggressive tumor behaviorPreferential incidenceGenesInflammatory genesSurvivinExpressionTumor behaviorSurvivin expressionAssociated gene signaturesTransgenic model
2003
Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome
HAUSLADEN DA, WHEELER MA, ALTIERI DC, COLBERG JW, WEISS RM. Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome. Journal Of Urology 2003, 170: 230-234. PMID: 12796695, DOI: 10.1097/01.ju.0000063685.29339.24.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalAgedAged, 80 and overAntibiotics, AntineoplasticAntigens, NeoplasmBCG VaccineBiomarkers, TumorCarcinoma, Transitional CellFemaleHumansImmunoblottingInhibitor of Apoptosis ProteinsMaleMicrotubule-Associated ProteinsMiddle AgedMitomycinNeoplasm ProteinsNeoplasm Recurrence, LocalPredictive Value of TestsPrognosisSurvivinTreatment OutcomeUrinary Bladder NeoplasmsConceptsTransitional cell carcinomaCompletion of treatmentBacillus Calmette-GuerinUrinary survivin levelsSurvivin levelsTCC recurrenceCalmette-GuerinUrine survivinIntravesical treatmentIntravesical instillationCell carcinomaMitomycin CRecurrent transitional cell carcinomaPrognostic molecular markersHigher survivin levelsUrinary survivinPosttreatment valuesRecurrenceMonthsHigher likelihoodSurvivinRemissionUrineTreatmentInstillationUrinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma
Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003, 62: 162-166. PMID: 12837459, DOI: 10.1016/s0090-4295(03)00134-1.Peer-Reviewed Original ResearchConceptsUrinary IL-8 levelsIL-8 levelsTransitional cell carcinomaBacille Calmette-GuérinIL-8Cell carcinomaCalmette-GuérinProstate cancerHealthy subjectsActive transitional cell carcinomaUrinary interleukin-8 levelsLow stage transitional cell carcinomaInterleukin-8 levelsBladder cancer cell linesBladder cancer cellsEnzyme-linked immunosorbentCancer cell linesIntravesical therapyInflammatory processInvasive tumorsAngiogenic factorsMitomycin CElevated levelsCancer cellsMitomycin C.
2002
Prostaglandin E2 Production and Cyclooxygenase-2 Induction in Human Urinary Tract Infections and Bladder Cancer
Wheeler MA, Hausladen DA, Yoon JH, Weiss RM. Prostaglandin E2 Production and Cyclooxygenase-2 Induction in Human Urinary Tract Infections and Bladder Cancer. Journal Of Urology 2002, 168: 1568-1573. PMID: 12352459, DOI: 10.1016/s0022-5347(05)64522-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBCG VaccineCyclooxygenase 1Cyclooxygenase 2DinoprostoneEnzyme InductionFemaleGene Expression Regulation, EnzymologicHumansIsoenzymesMaleMembrane ProteinsMiddle AgedProstaglandin-Endoperoxide SynthasesRNA, MessengerUreterUrinary BladderUrinary Bladder NeoplasmsUrinary Tract InfectionsUrogenital NeoplasmsUrotheliumConceptsUrinary prostaglandin E2 levelsUrinary tract infectionProstaglandin E2 levelsUrinary prostaglandin E2Tract infectionsBladder cancerProstaglandin E2 productionBCG treatmentCOX-2 mRNAUrogenital cancersE2 levelsUrine particulatesBladder muscleInflammatory processProstaglandin E2E2 productionBacillus Calmette-Guerin treatmentCOX-2 protein levelsCOX-2 protein expressionHuman urinary tract infectionsUrinary prostaglandin levelsCOX-2 expressionHuman bladder muscleBladder cancer casesCyclooxygenase-2 inductionBladder cancer detection with urinary survivin, an inhibitor of apoptosis.
Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Frontiers In Bioscience-Landmark 2002, 7: e36-41. PMID: 11815300, DOI: 10.2741/sharp.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisBiomarkersCarcinoma, Transitional CellChromosomal Proteins, Non-HistoneCystoscopyCytodiagnosisHumansImmunoblottingInhibitor of Apoptosis ProteinsMicrotubule-Associated ProteinsNeoplasm ProteinsNeoplasm Recurrence, LocalSensitivity and SpecificitySurvivinUrinary Bladder Neoplasms
2001
Urine Detection of Survivin and Diagnosis of Bladder Cancer
Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine Detection of Survivin and Diagnosis of Bladder Cancer. JAMA 2001, 285: 324-328. PMID: 11176843, DOI: 10.1001/jama.285.3.324.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBlotting, WesternFemaleHumansInhibitor of Apoptosis ProteinsMaleMicrotubule-Associated ProteinsMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalPrognosisProteinsReverse Transcriptase Polymerase Chain ReactionSensitivity and SpecificityStatistics, NonparametricSurvivinUrinary Bladder NeoplasmsUrogenital NeoplasmsUrologic DiseasesConceptsRecurrent bladder cancerUrinary tract diseaseBladder cancerUrine samplesTract diseaseHealthy volunteersSurvivin levelsProstate-specific antigen levelLow-grade bladder cancerPrognostic molecular markersNoninvasive diagnostic testTranscriptase-polymerase chain reactionCommon human cancersUrine survivinGenitourinary cancersProgression of cancerAggressive diseaseAntigen levelsCervical cancerUrology clinicPolymerase chain reactionUnfavorable outcomeCystoscopy resultsRT-PCR methodSurvivin detection
1999
Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer
Swana H, Grossman D, Anthony J, Weiss R, Altieri D. Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer. New England Journal Of Medicine 1999, 341: 452-453. PMID: 10438269, DOI: 10.1056/nejm199908053410614.Peer-Reviewed Original ResearchAgedApoptosisBiomarkers, TumorCarcinoma, Transitional CellDisease ProgressionFemaleHumansInhibitor of Apoptosis ProteinsMaleMicrotubule-Associated ProteinsMiddle AgedNeoplasm ProteinsNeoplasm Recurrence, LocalProteinsProto-Oncogene Proteins c-bcl-2SurvivinTumor Suppressor Protein p53Urinary Bladder NeoplasmsINDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER
SWANA H, SMITH S, PERROTTA P, SAITO N, WHEELER M, WEISS R. INDUCIBLE NITRIC OXIDE SYNTHASE WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal Of Urology 1999, 161: 630-634. PMID: 9915473, DOI: 10.1016/s0022-5347(01)61985-2.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellHumansImmunohistochemistryNitric Oxide SynthaseReverse Transcriptase Polymerase Chain ReactionUrinary Bladder NeoplasmsConceptsTransitional cell carcinomaNitric oxide synthaseInducible nitric oxide synthaseReverse transcriptase-polymerase chain reactionBladder tissueCell carcinomaInflammatory cellsNOS activityOxide synthaseNitric oxideTumor cellsGrades of TCCDistribution of iNOSImmunoreactive iNOS proteinHuman bladder tumorsTranscriptase-polymerase chain reactionIndividual tumor cellsControl bladder tissueCytostatic mediatorsINOS antibodyTumor immunoreactivityWestern blot analysisBladder tumorsTumor gradeImmune stimulation
1975
Palliative Urinary Diversion for Pelvic Malignancy
Brin E, Schiff M, Weiss R. Palliative Urinary Diversion for Pelvic Malignancy. Journal Of Urology 1975, 113: 619-622. PMID: 47918, DOI: 10.1016/s0022-5347(17)59536-1.Peer-Reviewed Original Research
1974
Hemorrhagic radiation cystitis Treatment
McGuire E, Weiss R, Schiff M, Lytton B. Hemorrhagic radiation cystitis Treatment. Urology 1974, 3: 204-208. PMID: 4812667, DOI: 10.1016/s0090-4295(74)80016-6.Peer-Reviewed Original Research
1973
Neoplasms of transitional cell origin in first twenty years of life
McGuire E, Weiss R, Baskin A. Neoplasms of transitional cell origin in first twenty years of life. Urology 1973, 1: 57-59. PMID: 4792287, DOI: 10.1016/0090-4295(73)90114-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentCarcinoma, Transitional CellChildHumansMaleNeoplasms, Multiple PrimaryUnited StatesUrinary Bladder Neoplasms